Henan Cancer Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1977-01-01
- Employees
- -
- Market Cap
- -
Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Not Applicable
Not yet recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT07047755
Efficacy and Safety of Prepectoral Prosthesis Immediate One-Stage Breast Reconstruction Versus Two-Stage Expander/Prosthesis Reconstruction in Postoperative Adjuvant Radiotherapy Breast Cancer Patients: A Prospective, Single-Center, Cohort Study
Recruiting
- Conditions
- Breast Cancer Patients
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 104
- Registration Number
- NCT07037576
- Locations
- 🇨🇳
Henan cacer hospital, Henan, Henan, China
Evaluation of the Effectiveness and Safety of Laparoscopic Assisted Mastectomy With Preservation of Nipple and Areola, Immediate One-step Breast Reconstruction With Pectoral Muscle Prosthesis and Patch, and Simultaneous Autologous Fat Transplantation
Not Applicable
Recruiting
- Conditions
- Breast Cancer Patients
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT07037537
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- Breast CancerHR+/HER2- Breast Cancer
- Interventions
- Drug: Nab-PE
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 238
- Registration Number
- NCT06967103
Organoid-guided Personalized Treatment of Pleural Effusion
Recruiting
- Conditions
- Lung Cancer
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06959173
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China
Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Solid Tumors
- Interventions
- Drug: SHR-A2102+HRS-4642
- First Posted Date
- 2025-05-02
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT06955390
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis
Phase 2
Recruiting
- Conditions
- NSCLC
- Interventions
- Drug: furmonertinib combined with anlotinib
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 146
- Registration Number
- NCT06945705
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, China
The Efficacy of Oral Cryotherapy in Preventing TROP2-ADC-Induced Oral Mucositis in Patients With Advanced Breast Cancer
Not Applicable
Not yet recruiting
- Conditions
- Advanced or Metastatic Breast Cancer
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 124
- Registration Number
- NCT06934733
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Phase 2
Recruiting
- Conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Interventions
- Drug: Albumin-Paclitaxel
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-06-23
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT06927180
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain
Phase 4
Not yet recruiting
- Conditions
- Opioid-Induced ConstipationPain Cancer
- Interventions
- Drug: Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-release Tablets
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 203
- Registration Number
- NCT06897917
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China